Ensysce Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ensysce Biosciences, Inc. on March 30, 2023, regarding events occurring on March 28, 2023. The Company, a Delaware corporation, announced the implementation of a reverse stock split and the redemption of its Series A Preferred Stock.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on corporate governance actions regarding capital structure.
Material Changes
- Reverse Stock Split: A one-for-twelve (1-for-12) reverse stock split of the Company's Common Stock was approved by stockholders and filed with the Delaware Secretary of State. The split became effective at 12:01 am on March 31, 2023.
- Trading Details: Post-split Common Stock began trading on March 31, 2023, under a new CUSIP number (293602405).
- Preferred Stock Redemption: All shares of Series A Preferred Stock were redeemed in accordance with their terms in connection with the reverse stock split.
- Adjustments to Equity Awards: Exercise prices and share counts for outstanding warrants, stock options, and restricted stock units were automatically adjusted proportionately. The number of shares reserved under the 2021 Omnibus Incentive Plan was reduced proportionately.
- Fractional Shares: No fractional shares were issued; holders received cash in lieu of fractions based on the average closing price of the five trading days preceding the effective date.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard mechanics of the stock split. The primary contingency noted is the cash settlement for fractional shares.
Key Facts for Investor Verification
- Verify the new CUSIP number (293602405) for post-split trading on Nasdaq.
- Confirm the adjusted exercise prices and share counts for any held stock options or warrants.
- Check brokerage statements for cash payments received in lieu of fractional shares.
- Confirm the complete redemption of Series A Preferred Stock holdings.